Abstract
The use of short acting GnRH agonist to trigger final oocyte maturation in IVF is a common practice. Its primary advantage is prevention of significant ovarian hyperstimulation syndrome. The effect of a long acting GnRH agonist preparation in that setting is not known. In the current case report, a depot preparation was given accidentally, resulting in prolonged and robust luteal phase activity, with luteolysis achieved only 14 days after administration. In that setting, fresh embryo transfer should be avoided.
Highlights
To the best of our knowledge, the use of depot GnRH agonist for final oocyte maturation was described only in the context of achieving ovarian suppression before chemotherapy [1]
While it was demonstrated that depot GnRH agonist is effective for final oocyte maturation, the luteal phase endocrine profile in general, and the timing of achieving ovarian suppression in particular, are not known
We hereby present a case report that confirms that final oocyte maturation can be achieved by depot GnRH agonist administration
Summary
To the best of our knowledge, the use of depot GnRH agonist for final oocyte maturation was described only in the context of achieving ovarian suppression before chemotherapy [1]. While it was demonstrated that depot GnRH agonist is effective for final oocyte maturation, the luteal phase endocrine profile in general, and the timing of achieving ovarian suppression in particular, are not known. We hereby present a case report that confirms that final oocyte maturation can be achieved by depot GnRH agonist administration.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
